Welcome to the GLIVEC Product Website

References

• American Cancer Society. Gastrointestinal stromal tumor (GIST). www.cancer.org. Accessed August 21, 2010.
• American Cancer Society. Stomach cancer. www.cancer.org. Accessed December 2, 2009.
• American Partnership for Eosinophilic Disorders (APFED). HES: information about hypereosinophilic syndrome. www.apfed.org/hes.htm. Accessed August 17, 2010.
• Anderson R. Soft tissue pathology. PowerPoint presentation at University of Illinois College of Medicine. UIC M2 Pathology. 2004.
• Baccarani M, Cortes J, Pane F, et al; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
• Balch CM, Bland KI, Brennan MF, et al. What is a surgical oncologist? Ann Surg Oncol. 1994;1(1):2-4.
• Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-625.
• Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626-632.
• Blay J-Y, Bonvalot S, Casali P, et al; for the GIST Consensus Meeting Panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16(4):566-578.
• Blay J-Y, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25(9):1107-1113.
• Bowne WB, Antonescu CR, Leung DHY, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88(12):2711-2720.
• Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-3338.
• Casali PG, Blay J-Y; for the ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;25(suppl 5):v98-v102.
• Chen C-SJ, Siegel DM. Dermatofibrosarcoma protuberans. www.emedicine.com/derm/topic97.htm. Updated July 23, 2010. Accessed August 17, 2010.
• Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753-1759.
• Chronic myelogenous leukemia treatment (PDQ^®): stage information. National Cancer Institute Web site. http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional/page2. Accessed September 28, 2010.
• Chronic myelogenous leukemia treatment (PDQ^®): general information. National Cancer Institute Web site. http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional/page1. Accessed September 28, 2010.
• Cleveland Clinic Web site. What is leukemia? http://cms.clevelandclinic.org. Accessed August 17, 2010.
• Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22(18):3813-3825.
• Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557-586.
• Cortes JE. Treatment approach to chronic-phase chronic myelogenous leukemia. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: McGraw-Hill; 2007:177-188.
• Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer. 1995;76(12):2393-2417.
• Data on file. Novartis Pharmaceuticals Corporation. East Hanover, NJ.
• Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011;37(1):75-88.
• Deininger M, O’Brien SG, Guilhot F, et al. International Randomized Study of Interferon and STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Poster presented at: 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA.
• Deininger MWN, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637-1647.
• DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene c-kit, and a molecular inhibitor (STI571). Ann Surg Oncol. 2002;9(9):831-839.
• DeMatteo RP, Ballman KV, Antonescu CR, et al; for the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104.
• DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112(3):608-615.
• DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-58.
• Demetri GD. Gastrointestinal stromal tumors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. Vol 1. 8^th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:1204-1217.
• Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(suppl 2):S1-S41.
• Dictionary of cancer terms. National Cancer Institute Web site. http://www.cancer.gov/dictionary. Accessed April 29, 2010.
• Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002;1(1):31-36.
• Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99(1):42-47.
• Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98(7):1337-1354.
• Faderl S, Kantarjian HM. Myelodysplastic syndromes. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. DaVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Vol 2. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:2292-2304.
• Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459-465.
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7):1247-1253.
• Gleevec^® (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.
• Glivec^® (imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2010.
• Glivec®(imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2012.
• Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol.1996;35(3, pt 1):355-374; quiz 375-376.
• Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004;9(3):271-281.
• Harrison ML, Goldstein D. Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach. Intern Med J. 2006;36(6):367-377.
• Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360-5367.
• Hernández JM, del Cañizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11(4):441-444.
• Hochhaus A, O'Brien SG, Guilhot F, et al; for the IRIS investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-1061.
• Hughes TP, Hochhaus A, Branford S, et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the International Randomized Study of Interferon Versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP). Blood. 2008;112(11):Abstract 334.
• Iacobucci I, Saglio G, Rosti G, et al; for the GIMEMA Working Party on Chronic Myeloid Leukemia. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006;12(10):3037-3042.
• Joensuu H. Current perspectives on the epidemiology of gastrointestinal stromal tumours. Eur J Cancer Suppl. 2006;4(suppl 1):4-9.
• Joensuu H. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO) [ASCO abstract LBA1]. J Clin Oncol. 2011;29(18S):775s
• Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3(11):655-664.
• Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. [published online ahead of print May 28, 2010]. Cancer Treat Rev. doi:10.1016/j.ctrv.2010.04.008.
• Kamineni P, Baptiste A, Hassan M, et al. Case of chronic eosinophilic leukemia with deletion of chromosome 16 and hepatitis C. J Natl Med Assoc. 2006;98(8):1356-1360.
• Kantarjian HM, Cortes J, La Rosée P, Hochhaus A. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer. 2010;116(6):1419-1430.
• Kang Y, Kang BW, Ryu M, et al. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors with c-kit exon 11 mutation [abstract 515P]. Ann Oncol. 2008;19(suppl 8):169.
• Karnak D, Kayacan O, Beder S, Delibalta M. Hypereosinophilic syndrome with pulmonary and cardiac involvement in a patient with asthma. CMAJ. 2003;168(2):172-175.
• Kindblom L-G, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259-1269.
• Kontogianni-Katsarou K, Lariou C, Tsompanaki E, et al. KIT-negative gastrointestinal stromal tumors with a long term follow-up: a new subgroup does exist. World J Gastroenterol. 2007;13(7):1098-1102.
• Le Cesne A, Van Glabbeke M, Verweij J, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27(24):3969-3974.
• Lehane E, McCarthy G. Medication non-adherence—exploring the conceptual mire. Int J Nurs Pract. 2009;15(1):25-31.
• Li J, Gong FJ, Li J, Wu WA, Shen L. Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: analysis from a single-center contrast study [abstract 10556]. J Clin Oncol. 2009;27(15S, pt 1):549s.
• Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 2005;1754(1-2):3-13.
• Manley P, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445-453.
• Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieved complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-2388.
• McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol. 2004;31(2)(suppl 6):30-36.
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.
• Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003;54(1):3-24.
• The NCCN Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology (Version 1.2011). © 2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org Accessed August 30, 2010.To view the most recent and complete version of the guidelines, go online to http://www.nccn.org.
• NCCN Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology (Version 2.2010). ©2010. National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed February 4, 2010. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
• NCCN Dermatofibrosarcoma Protuberans Clinical Practice Guidelines in Oncology (Version 1.2010). ©2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed August 27, 2010. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
• NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 2.2010). ©2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed April 15, 2010. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
• National Cancer Institute. General information about myelodysplastic/myeloproliferative diseases. www.cancer.gov/cancertopics/pdq/treatment/mds-mpd/HealthProfessional. Accessed August 24, 2010.
• Nishida T, Kumano S, Sugiura T, et al. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. Am J Roentgenol. 2003;180(1):185-189.
• Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401-5411.
• O'Brien S, Guilhot F, Druker B, et al. The IRIS study in early chronic phase CML: 7 year follow-up. Slides presented at: 50th Annual Meeting and Exposition of the American Society of Hematology; December 6-9, 2008; San Francisco, CA.
• Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia. Hematology Am Soc Educ Program. 2005:118-122.
• Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008;44(4):501-509.
• Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17(9):2941-2953.
• Reichardt P, Blay J-Y, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2010;10(2):221-232.
• Reichardt P, Hartmann JT, Sundby Hall K, et al.Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment—the first analysis in the SSG XVIII/AIO trial patient population [ESMO abstract 31LBA]. Eur J Cancer. 2011;47(suppl 2):15.
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56-66.
• Saglio G, Kim D-W, Issaragrisil S, et al; for ENESTnd investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259.
• Samavedi V, Sacher RA, Herrin VE, Files JC, Zhou Y, Schick P. Hypereosinophilic syndrome. www.emedicine.com/­med/topic1076.htm. Updated October 4, 2009. Accessed August 17, 2010.
• Scandinavian Sarcoma Group and Sarcoma Group of the AIO, Germany. Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST with a high risk for recurrence: a randomized phase III study. Clinical study protocol-SSG XVIII (GIST). http://www.ssg-org.net. Published February 2008. Accessed November 21, 2008.
• Schaffer SD, Yoon SJ. Evidence-based methods to enhance medication adherence. Nurse Pract. 2001;26(12):44, 50, 52, 54.
• Schaffer SD, Yoon S-JL. Evidence-based methods to enhance medication adherence. Nurse Pract. 2001;26(12):44-54.
• Schwartz RS. The hypereosinophilic syndrome and the biology of cancer. N Engl J Med. 2003;348(13):1199-1200.
• Stojadinovic A, Karpoff HM, Antonescu CR, et al. Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol. 2000;7(9):696-704.
• Sutent^® (sunitinib malate) summary of product characteristics. Sandwich, Kent, UK: Pfizer Ltd; 2010.
• Sutent® (sunitinib malate) summary of product characteristics. Sandwich, Kent, UK: Pfizer Ltd; 2011.
• Swansbury J. The myeloid disorders: background. In: Swansbury J, ed. Cancer Cytogenetics: Methods and Protocols. Vol 220. Totowa, NJ: Humana Press; 2010:23-42.
• Tasigna^® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; 2007.
• Tasigna^® (nilotinib) summary of product characteristics. Basel, Switzerland: Novartis Pharma AG; December 2010.
• The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 2.2010).©2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed August 28, 2010. To view the most recent and complete version of the guidelines, go online to www.nccn.org.
• The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 2.2011).©2011 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed August 4, 2011. To view the most recent and complete version of the guidelines, go online to www.nccn.org.
• Thomas DA. Philadelphia chromosome—positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program. 2007:435-443.
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
• Verweij J, Casali PG, Zalcberg J, et al; for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, and the Australasian Gastrointestinal Trials Group. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-1134.
• Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 2001;8(3):161-173.